LifeHealthcare Orthopaedics and NuVasive Joins Forces with a Unique Product and Renowned Surgeons, to Give Amputees a Real Chance of Receiving Life Changing Prosthetics
On Thursday 17th and Friday 18th March Dr Munjed Al Muderis and Dr Kevin Tetsworth and their surgical team at Norwest Private Hospital, conducted the first two operations in Australia to magnetically lengthen short residual femoral bone. The development of the PRECICE Freedom Nail by Ellipse Technology, now part of NuVasive Specialized Orthopaedics™ provides surgeons with the ability to extend the residual bone by using a combination of rare-earth magnets and patented gears located inside the Telescoping Nail. These are the very first implantations of the PRECICE Freedom Nail in the Asia Pacific region!
Professor Al Muderis runs the Osseo-Integration Group in Australia http://www.osseointegrationaustralia.com.au/ and has conducted over 200 Osseo-integration procedures. Dr Tetsworth is the International President of ASAMI-BR http://www.asami-br.com/
When asked what this means for patients, Fraser Cleve, General Manager, LifeHealthcare Orthopaedics, Australia, replied “Whilst these patients are at the start of their journey and have a long way to go with their post-operative care, they have been given a real chance, that following lengthening, that they will be able to be fitted with an Osseo-integration device with an advanced prosthetics leading to a much better quality of life. We look forward to supporting the surgeons, limb lengthening coordinators and patients in their rehabilitation clinics over the coming months”.
PRECICE Freedom Nail
In this first operation, the patient lost their leg in an accident as a child. The mid-thigh amputation left a residual bone too short to operate on until the PRECICE Freedom Nail became available.
A femoral osteotomy was done with fixation of the Nail above and below with locking bolts and cabling. Once the femur is lengthened and consolidated, the PRECICE Nail can be removed and an Osseo-integration device implanted. The patient will then have access to an advanced prosthetic.
Limb – before PRECICE Freedom Nail
Limb – after PRECICE Freedom Nail
It would not have been possible to support Dr Al Muderis and Dr Tetsworth help their patients, without the efforts of many people and departments working as a team. Particular thanks go to the Ellipse / NuVasive Specialized Orthopaedics™ design teams and LifeHealthcare Customer Service, Operations and Clinical Support.
LifeHealthcare Orthopaedics team is proud to have been a part of these life changing events and as a specialist lower limb ‘complex surgery’ team we work with the leading Australian and New Zealand Paediatrics, Tumour, Complex Revision and Amputation surgeons.
We are proud to run distribution of the PRECICE Nail portfolio and to offer pre-operative planning, clinical solution and post-op operative support to our surgeons on behalf of NuVasive Specialized Orthopedics™”.
To find out more about LifeHealthcare and keep up to date with the great work the team are doing, be sure to follow us on LinkedIn.
Last week LifeHealthcare said goodbye to our first ever round of interns. Commencing late last year, the group of six from two New South Wales universities worked with a number of areas in the business, from marketing to operations, undertaking hands on, engaging projects.
Projects included market segmentation, building specialised marketing materials, customer journey planning, process mapping and a very successful engineering project.
Their internships concluded with presentations to the Executive Leadership team, the intern mentors and other LifeHealthcare employees and a well-earned celebration dinner.
Matt Muscio, LifeHealthcare CEO, remarked “…the intern program was a resounding success, with some great insights developed, as well as some excellent engineering research conducted. These are the first interns we’re engaged at LifeHealthcare and with the tangible business outcomes achieved, as well as the energy and vibrancy they brought to the business, they certainly will not be the last”.
The interns also got a lot out of their time at LifeHealthcare, being able to put theory into practice in a real life setting.
Linn Mollberg, who will remain with LifeHealthcare as a Marketing Associate, had this to say about the experience “[The internship with] LifeHealthcare has enabled me to gain real life experience in strategic marketing by leading a market development project. I’m very pleased to be continuing at LHC as a part-time employee, working alongside the best people in the industry”.
LifeHealthcare is not your typical multinational and employs nearly 200 people across Australia and New Zealand. With the success of our intern program for 2015/2016, we’ll be on the lookout for top quality undergraduates for out 2016/2017 program, so keep following us for updates and details.
L to R (Back) Joel McCabe, Michael Ho, Linn Mollberg
L to R (front) Zac Schwartz, Sally Gao, Ariella Naumburger
Orlando, Fla., March Mazor Robotics Renaissance® Guidance System Helping Patients with OCD5Mazor Robotics, a global leader in the development and distribution of innovative surgical guidance systems for spine and brain surgery, announced today the first Deep Brain Stimulation (DBS) surgery performed with its Renaissance®Guidance System to treat patients with Obsessive Compulsive Disorder (OCD).
On February 23, 2015, Dr. David VanSickle of South Denver Neurosurgery was the first physician to utilize the Renaissance Guidance System to successfully perform the DBS procedure to treat OCD on 30-year-old twins at Littleton Adventist Hospital in Littleton, Colorado, part of Centura Health’s Neurosciences system of care.
“DBS involves placing implantable neurostimulators (electrodes) in targeted areas of the brain,” said Dr. VanSickle. He added, “The key is to place the device precisely inside the brain to minimize brain tissue damage. This is where the Renaissance® Guidance System comes into play. It allows me to increase surgical accuracy and precisely hold the trajectory. It is groundbreaking technology that is great news for patients suffering from this debilitating disease.”
After the procedure, all electrodes were verified by intra-operative CT to be placed in the intended location to an accuracy of less than a millimeter.
“This milestone is another testimony to our commitment to improving the art and science of spine and brain surgery, with one main focus: improving patient care,” said Ori Hadomi, CEO of Mazor Robotics.
According to the National Institute of Mental Health, OCD affects about 2.3% of the US population aged 18 to 54 years (3.3 million Americans). An additional one million children and adolescents have the disorder. If left untreated, OCD symptoms become progressively worse, making it difficult to function at school, at work, and at home. Treatment is therefore crucial. Initial approaches to OCD treatment include pharmacological, therapeutic, and self-help methods. However, when severe OCD proves resistant to the typical standard of care, physicians may turn to DBS as a surgical option.
About Mazor Robotics
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for Mazor Robotics, including without limitation, statements regarding the possibilities of the Renaissance system in DBS procedures for OCD, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 9, 2014 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.